StockTipsArenaBeta

BUY Marksans Pharma Limited — Aastha Jain, Hem Securities

BUYMarksans Pharma Limited
Marksans Pharma share price target & all analyst calls

byAastha Jain, Hem SecuritiesHorizon: NA (inferred Swing (≤2wk))13 Aug 2026via Zee Business (Live)

Entry₹313Inferred
Target₹330
Total upside +5.43% (call closed)
Stop loss₹285-8.95% risk
Exit₹33014 Aug 2026, 2:00 pm
Target hit+5.43%0.00%upside left
Follow Aastha Jain for new calls(30% target hit, 79 closed calls)Get alertsWatch MARKSANS for new buy/sell callsGet alertsSee 105 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 14 Aug 2026
5 supporting1 neutral0 opposing
Supports the BUY call (5)

Marksans Pharma shares rally over 9% after Q1 profit spikes 174% YoY to Rs 159 crore

NewsEt-Markets·12 Aug · yesterday

(opens in new tab)

Marksans Pharma Q1 Results: Shares jump 11% after profit nearly triples, margin expands

NewsCnbc-Tv18·12 Aug · 2d ago

(opens in new tab)

Marksans Pharma reported record Q1FY27 results with all-time high profitability and cash balance crossing ₹1,000 crore. EBITDA rose 113% YoY to ₹213 crore, and PAT grew 174% YoY to ₹159 crore. UK & Eu

NSE · Press Release·12 Aug · 2d ago

(opens in new tab)

Marksans Pharma reported record Q1FY27 financial results with all-time high profitability and cash balance exceeding ₹1,000 crore. EBITDA rose 113% YoY to ₹213 crore, and PAT grew 174% YoY to ₹159 cro

BSE · Company Update·12 Aug · 2d ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·11 Jun · 2mo ago

Neutral / worth noting (1)

Marksans Pharma Ltd announced that its Board of Directors approved the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026, during a meeting held on August 12

BSE · Board Meeting·12 Aug · 2d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Marksans Pharma

All analyst calls on Marksans Pharma

More from Aastha Jain, Hem Securities

Every call and its outcome